source data for table 1 (6)

elife-26129-v3.xml

10.7554/eLife.26129.015

Table 1.Summary of FXR1-knockdown-induced anti-proliferation in cancer cell lines and CRISPR-Cas9-engineered cell clones.

The cell line or CRISPR clone name, cancer type, TP53 and FXR2 copy number alteration (based on the CCLE database or knockout confirmation), FXR1-sh3 knockdown (KD) efficiency (determined by q-RT-PCR and WB), and FXR1 KD-induced anti-proliferation efficiency are listed. Dark green, anti-proliferation efficiency >60%. Yellow green, anti-proliferation 30–60%. Yellow, anti-proliferation <30%. Data of KD efficiency and anti-proliferation efficiency represent means of at least three independent experiments. Del, deletion; WT, copy number normal; KO, knockout.

10.7554/eLife.26129.016Table 1—source data 1.Source data for <xref ref-type="table" rid="table1">Table 1</xref>.

	Cell	Cancer	TP53	FXR2	FXR1 KD efficiency (%)	FXR1 KD induced anti-proliferation (%)
Cancer cell line	HL-60	Acute myeloid leukemia	Del	Del	77.6	73.4
	KATOIII	Gastric	Del	Del	83.5	76.4
	KMS-11	Multiple myeloma	Del	Del	95.7	88.3
	H358	Lung	Del	Del	79.9	95.3
	H1299	Lung	Del	WT	96.4	−1.1
	L540	Hodgkin lymphoma	Del	WT	94.9	−5.8
	MG-63	Osteosarcoma	Del	WT	96.8	−4.5
	SKOV3	Ovarian	Del	WT	89.0	−7.3
	Hep3B	Liver	WT	Del	94.0	−0.8
	A549	Lung	WT	WT	72.7	15.5
	AGS	Gastric	WT	WT	73.6	12.8
	HepG2	Liver	WT	WT	92.0	2.8
	MKN45	Gastric	WT	WT	71.5	3.4
CRISPR-Cas9 KO clone	DKO1	Gastric	WT	WT	88.8	1.9
	DKO5	Gastric	WT	WT	86.0	2.7
	DKO11	Gastric	KO	KO	79.0	49.8
	DKOL7-1	Gastric	KO	KO	92.0	68.5
	DKOL7-3	Gastric	KO	KO	87.5	45.3
	FXR2 KO10	Gastric	WT	WT	80.6	34.1
	FXR2 KO11	Gastric	WT	WT	75.8	19.0
	FXR2 KO17	Gastric	WT	WT	77.2	6.8
	FXR2 KO5	Gastric	WT	KO	81.3	16.2
	FXR2 KO16	Gastric	WT	KO	72.9	15.6
	TP53 KO3-3	Gastric	WT	WT	51.1	−5.3
	TP53 KO3-10	Gastric	WT	WT	92.9	−5.8
	TP53 KO3-6-1	Gastric	KO	WT	85.3	34.0
	TP53 KO3-6-2	Gastric	KO	WT	81.4	−5.3
	TP53 KO3-14-6	Gastric	KO	WT	86.2	12.5

elife-31549-v1.xml

10.7554/eLife.31549.006

Table 1.Baseline characteristics of the participants included in analysis.

10.7554/eLife.31549.007Table 1—source data 1.Source data for <xref ref-type="table" rid="table1">Table 1</xref>.

		LD-SP/SP	LD-SP/PIP	LD-PIP/PIP	LD-PIP/SP
No. subjects		n = 4	n = 4	n = 4	n = 4
Treatment 1 (T1)		Sulfadoxine-pyrimethamine 500 mg/25 mg	Sulfadoxine-pyrimethamine 500 mg/25 mg	Piperaquine 480 mg	Piperaquine 480 mg
Treatment 2 (T2)		Sulfadoxine-pyrimethamine 1000 mg/50 mg	Piperaquine 960 mg	Piperaquine 960 mg	Sulfadoxine-pyrimethamine 1000 mg/50 mg
Sex
Male	n (%)	2 (50%)	0 (0%)	1 (25%)	1 (25%)
Female	n (%)	2 (50%)	4 (100%)	3 (75%)	3 (75%)
Age	Mean (range)	24.5 (21–29)	24 (21–28)	21.5 (20–24)	22.5 (20–27)
BMI (kg/m²)	Mean (range)	21 (18–23)	22 (19–25)	24.5 (21–27)	26.5 (24–29)

elife-31549-v2.xml

Table 1.Baseline characteristics of the participants included in analysis.

Table 1—source data 1.Source data for <xref ref-type="table" rid="table1">Table 1</xref>.

		LD-SP/SP	LD-SP/PIP	LD-PIP/PIP	LD-PIP/SP
No. subjects		n = 4	n = 4	n = 4	n = 4
Treatment 1 (T1)		Sulfadoxine-pyrimethamine 500 mg/25 mg	Sulfadoxine-pyrimethamine 500 mg/25 mg	Piperaquine 480 mg	Piperaquine 480 mg
Treatment 2 (T2)		Sulfadoxine-pyrimethamine 1000 mg/50 mg	Piperaquine 960 mg	Piperaquine 960 mg	Sulfadoxine-pyrimethamine 1000 mg/50 mg
Sex
Male	n (%)	2 (50%)	0 (0%)	1 (25%)	1 (25%)
Female	n (%)	2 (50%)	4 (100%)	3 (75%)	3 (75%)
Age	Mean (range)	24.5 (21–29)	24 (21–28)	21.5 (20–24)	22.5 (20–27)
BMI (kg/m²)	Mean (range)	21 (18–23)	22 (19–25)	24.5 (21–27)	26.5 (24–29)

elife-32506-v1.xml

10.7554/eLife.32506.022

Table 1.Frequency of cell-intercalation events.

10.7554/eLife.32506.023Table 1-source data 1Source data for <xref ref-type="supplementary-material" rid="table1sdata1">Table 1</xref>.

Genotype	Frequency of intercalation (%)			n
Genotype	Leftward	Rightward	Total	n
+/+	4.0	4.8	9.2*	250
Myo31DF	2.2	3.3	6.0*	182

Frequency is defined as the number of intercalation events divided by the total number of examined cells, in 30 min.

When two cells in a column had initial contact and were subsequently separated by another intervening cell, cell intercalation was said to occur, and the direction from which the intervening cell came was determined.

*includes one event that was not distinguished as leftward or rightward.

elife-44889-v2.xml

10.7554/eLife.44889.016

Table 1.List of the 41 hit compounds that rescued the expression of both <italic>vcanb</italic> and <italic>mbp</italic> in <italic>adgrg6<sup>tb233c</sup></italic> mutants, thus representing putative Adgrg6 pathway modulators.

The table includes the plate and well ID, along with known activities and the average score from nine adgrg6^tb233c embryos in the vcanb assay, from six adgrg6^tb233c embryos in the mbp assay and from three adgrg6^fr24 embryos in the fr24 assay. Grey shading indicates compounds presumed to interact with Adgrg6 receptor directly; yellow shading indicates compounds presumed to be downstream effectors of the pathway. Abbreviations: DE, dead embryos; ND, no data; S, Spectrum; T, Tocris. *Note that cilnidipine can rescue fr24 at 40 µM (data not shown). See also Table 1—source data 1.

10.7554/eLife.44889.017Table 1—source data 1.Source data for <xref ref-type="table" rid="table1">Table 1</xref>.

#	Plate	Well	Compound name	Known activity	vcanb score	mbp score	fr24 score
1	S18	C09	CARAPIN-8(9)-ENE	undetermined	0.00	8.50	9.00
2	S25	D08	3-ISOBUTYL-1-METHYLXANTHINE (IBMX)	phosphodiesterase inhibitor, non-selective adenosine receptor antagonist	2.00	8.50	9.00
3	S17	F05	DEOXYGEDUNIN	neuroprotective	2.00	8.00	9.00
4	S23	F10	DIHYDROFISSINOLIDE	undetermined	2.67	7.50	9.00
5	S04	B02	IVERMECTIN	antiparasitic	2.33	7.00	9.00
6	T01	F06	SC-10	protein kinase C activator, NMDA receptor activator	5.67	6.50	9.00
7	T01	H11	1,3-Dipropyl-8-phenylxanthine	Selective adenosine A1 receptor antagonist	3.33	6.50	9.00
8	S17	E02	3-DEOXO-3beta-ACETOXYDEOXYDIHYDROGEDUNIN	undetermined	0.00	6.50	9.00
9	T11	F07	Cilnidipine*	dihydropyridine N- and L-type Ca²⁺ channel blocker	2.00	6.50	9.00
10	S13	F03	AMIODARONE HYDROCHLORIDE	coronary vasodilator, Ca²⁺ channel blocker	5.00	6.50	9.00
11	S06	E02	HYDROCORTISONE HEMISUCCINATE	glucocorticoid	3.67	6.00	9.00
12	T01	C04	(RS)-(Tetrazol-5-yl)glycine	highly potent NMDA receptor agonist	3.00	5.00	9.00
13	S02	E05	LOMEFLOXACIN HYDROCHLORIDE	antibacterial	5.33	5.00	9.00
14	S13	E04	ETHAMIVAN	CNS & respiratory stimulant	4.67	5.00	9.00
15	T08	B04	CGS 15943	potent adenosine receptor antagonist	5.33	4.50	9.00
16	S13	E09	ASTEMIZOLE	H1 antihistamine (nonsedating)	4.67	4.50	9.00
17	T02	A09	SKF 91488 dihydrochloride	histamine N-methyltransferase inhibitor	3.00	4.00	9.00
18	S25	F05	11alpha-HYDROXYPROGESTERONE HEMISUCCINATE	glucocorticoid	2.67	4.00	9.00
19	T14	A07	Efonidipine hydrochloride monoethanolate	dihydropyridine L-type and T-type Ca²⁺ channel blocker	3.67	4.00	9.00
20	T05	C09	Nifedipine	dihydropyridine L-type Ca²⁺ channel blocker	4.33	7.00	8.00
21	T05	E08	CGP 37157	antagonist of mitochondrial Na⁺/Ca²⁺ exchange	3.67	6.50	8.00
22	S05	D03	DANAZOL	anterior pituitary suppressant, anti-estrogenic	1.00	5.00	8.00
23	S18	H09	XANTHYLETIN	undetermined	1.00	4.50	8.00
24	S18	A06	FERULIC ACID	antineoplastic, choleretic, food preservative	3.67	4.00	8.00
25	S18	F02	alpha-DIHYDROGEDUNOL	undetermined	2.33	4.00	8.00
26	T05	F04	(S)-(+)-Niguldipine hydrochloride	dihydropyridine L-type Ca²⁺ channel blocker, α1 antagonist	3.67	5.00	7.00
27	T07	F02	Tracazolate hydrochloride	subtype-selective GABA_Aallosteric modulator	2.33	4.50	7.00
28	S10	E02	NIMODIPINE	dihydropyridine L-type Ca²⁺ channel blocker	0.33	7.00	6.00
29	S17	E06	3beta-ACETOXYDEOXODIHYDROGEDUNIN	undetermined	2.00	4.50	5.00
30	S17	F02	DIHYDROGEDUNIN	undetermined	1.67	5.00	2.00
31	S22	F09	TANGERITIN	undetermined	1.33	5.50	1.00
32	S10	F07	COLFORSIN	adenylate cyclase activator, antiglaucoma, hypotensive, vasodilator	0.00	9.00	0.00
33	T04	G02	Imiloxan hydrochloride	selective α_2B-adrenoceptor antagonist	0.67	9.00	ND
34	S24	C03	3alpha-ACETOXYDIHYDRODEOXYGEDUNIN	undetermined	0.33	8.50	DE
35	S11	E02	EZETIMIBE	antihyperlipidemic (sterol absorption inhibitor)	2.00	7.50	0.00
36	S10	E06	NITRENDIPINE	dihydropyridine L-type Ca²⁺ channel blocker	1.33	7.00	ND
37	S11	E08	ROSUVASTATIN CALCIUM	antihyperlipidemic	0.00	6.00	0.00
38	S22	C07	DEMETHYLNOBILETIN	undetermined	0.00	6.00	0.00
39	S22	G11	HEXAMETHYLQUERCETAGETIN	undetermined	0.00	5.50	DE
40	S22	F08	NOBILETIN	matrix metaloproteinase inhibitor, antineoplastic, anti-ERK, NF-κB suppressor	0.00	5.00	DE
41	S12	H07	PREGNENOLONE SUCCINATE	glucocortcoid, antiinflammatory	4.67	4.00	DE

elife-54275-v1.xml

Table 1.Comparison of parameters between orexin neuron-ablated mice and orexin MCH-blated mice.

Table 1—source data 1.Source data for <xref ref-type="table" rid="table1">Table 1</xref>.

Parameter	Orexin neuron-ablated mice	Orexin and MCH-ablated mice	- fold Difference (OXMC/OX)	P value
Earliest detection timing of cataplexy	2 weeks post-ablation	2 weeks post-ablation	N/A	N/A
Time-of-day occurrence at 4 weeks	Both light and dark phases	Both light and dark phases	N/A	N/A
Total time in wakefulness during dark phase at 4 weeks	418.9 ± 20.2 min	571.0 ± 22.2 min	1.36	1.4E-03
Total time in NREM sleep during dark phase at 4 weeks	258.3 ± 16.2 min	90.5 ± 19.8 min	0.35	2.8E-04
Total time in REM sleep during dark phase at 4 weeks	25.6 ± 0.9 min	2.7 ± 1.7 min	0.10	4.3E-06
Total time in wakefulness during light phase at 4 weeks	278.1 ± 19.7 min	322.6 ± 7.3 min	1.16	3.1E-02
Total time in NREM sleep during light phase at 4 weeks	389.8 ± 17.4 min	340.1 ± 8.1 min	0.87	1.6E-02
Total time in REM sleep during light phase at 4 weeks	46.3 ± 3.4 min	20.8 ± 4.2 min	0.45	2.7E-03
Total time in cataplexy in dark phase at 4 weeks	11.0 ± 0.6 min	31.2 ± 3.6 min	2.83	2.6E-03
Number of cataplexy bouts in dark phase at 4 weeks	14.8 ± 2.0	16.9 ± 2.1	1.14	0.53
Mean bout duration in dark phase at 4 weeks	53.3 ± 7.6 sec	113.0 ± 9.6 sec	2.12	2.2E-03
Total time in cataplexy in light phase at 4 weeks	5.4 ± 0.9 min	24.2 ± 4.5 min	4.45	1.4E-02
Number of cataplexy bouts in light phase at 4 weeks	8.3 ± 1.4	15.4 ± 3.1	1.87	0.13
Mean bout duration in light phase at 4 weeks	50.0 ± 11.4 sec	96.3 ± 4.8 sec	1.93	1.7E-03